Finally, I got around to visiting that "Medline" site and their rather questionable rating system. Presumptious I would say now, but I'll look into it further at some point in time. I'm providing the executive summary and clinical context of pycnogenol courtesy of Medscape. I might add that there are several companies making/selling pine bark extract. It is not necessary to buy the most expensive brand. And now this; Medscape does not endorse products and recommends that health professionals be consulted.
Pycnogenol is a naturally occurring compound found in French maritime pine bark. Chemically, Pycnogenol is a combination of procyanidins and phenolic acids and is purported to have significant antioxidant effects, in part by enhancing the actions of vitamins C and E.
A review by Rohdewald, published in the April 2002 issue of the International Journal of Pharmacology and Therapeutics, noted that Pycnogenol had been demonstrated to be effective as a preventive or therapeutic medicine in a wide range of conditions, including sunburn, asthma, systemic lupus erythematosus, and, possibly, hypertension and cardiovascular disease. Pycnogenol was also suggested to improve symptoms of premenstrual syndrome, including abdominal cramps.
The current study examines whether Pycnogenol could improve cramps and abdominal pain among athletes as well as patients with diabetes and peripheral vascular disease.
Study Highlights
The first part of the study was an open-label trial of Pycnogenol among 3 patient groups: healthy subjects with cramps at least 4 times per week, patients with chronic venous insufficiency and cramps 4 to 6 times per week, and athletes who experienced cramps at least 8 times weekly during athletic events. All subjects also reported moderate to severe muscular pain at least 3 days per week. Individuals with other medical illnesses or who were receiving any other medications were not eligible for this trial.
Participants received 50 mg of Pycnogenol 4 times daily along with a recommendation to drink at least 1.5 L of water daily. The treatment period lasted 4 weeks.
Study outcomes included the frequency of cramps and a 10-point visual analog scale of muscular cramps and pain.
The study cohort included 22 individuals in the healthy patient subgroup, 21 patients with venous insufficiency, and 23 athletes. Equal numbers of men and women participated in the trial.
Mean baseline frequency of cramps per day in the healthy patient, patient with venous insufficiency, and athletic patient groups were 4.8, 6.3, and 8.6, respectively. These mean values decreased to 1.3, 2.6, and 2.4 cramps per day in the 3 groups, respectively, after 4 weeks of treatment with Pycnogenol. The visual analog scores for muscle cramping and pain also decreased significantly with treatment in all participant subgroups, and follow-up evaluations of cramp severity and frequency demonstrated a significant effect for Pycnogenol for 1 week following the end of study treatment.
The second part of the study was a placebo-controlled test of 100 mg of Pycnogenol twice daily. Subjects included patients with intermittent claudication, defined by symptoms on a defined treadmill protocol, and patients with diabetes and microangiopathy and neuropathy. The treatment period was 4 weeks, and the outcome measures were again the frequency and severity of muscular cramping and pain.
25 patients with intermittent claudication participated in the trial along with 22 patients with diabetic microangiopathy.
The mean numbers of cramping episodes per day at baseline were 9.5 and 8.9 in the claudication and diabetes groups, respectively. These mean respective levels decreased to 3.2 and 3.0 episodes per day with study treatment. Pycnogenol was superior to placebo in this outcome.
While analog measurements of muscular cramping and pain remained stable in the placebo group during the treatment phase, Pycnogenol significantly improved symptoms. Again, the positive effects of Pycnogenol remained evident for 1 week following cessation of study therapy.
There were no adverse events associated with study treatment.
Pearls for Practice
A previous review of Pycnogenol suggested that this naturally occurring compound could be effective in the prevention or management of a variety of maladies, including sunburn, asthma, systemic lupus erythematosus, premenstrual syndrome, and, possibly, hypertension and cardiovascular disease.
The current study demonstrates that Pycnogenol can reduce the frequency and severity of muscle cramps among healthy patients; athletes; and patients with chronic venous insufficiency, intermittent claudication, and diabetes with microangiopathy. Treatment effects lasted for 1 week beyond the end of Pycnogenol therapy, and there were no adverse events associated with treatment.
My personal opinion is that the NOX theory is incorrect. This seems to crop up every time that a drug or patent medicine improves blood flow. Somehow, pycnogenol is changing the population and order of prostaglandins thus having wide ranging effects too numerous to recount here even if I could.